Telomir Pharmaceuticals, Inc.
Tremor tracks 1 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
None right now.
Trials
Key executives leaving
From the last 12 months of the company's SEC reports.
None found.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 0 purchases
No insider sales or purchases in the last 6 months.
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- Quarterly reportQuarterly report (10-Q)Nov 6, 2026
- Permission to sell new sharesPermission to sell new shares (S-3)Oct 27, 2026
- Signed a major agreement; Shared information with investorsNews report (8-K)Oct 6, 2026
- Shared information with investorsNews report (8-K)Sep 17, 2026
- News reportNews report (8-K)Sep 16, 2026
- Shared information with investorsNews report (8-K)
Money left
Coming soon: how many months of cash the company has, from its quarterly reports.